Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Medical Focus

New accomplishment in gene therapies


A clinical trial for a gene therapy to treat a severe immunodeficiency has provided highly promising initial results. Of nine patients treated and monitored over one to three years in the United Kingdom and the United States, seven had no infections and six were freed from treatments for disease complications.
Reference in Nature Medicine >
Laboratory technician Laboratory technician

Two of Genopole’s key actors in innovative biotherapies, the laboratory Genethon and the gene therapy production facility Yposkesi, contributed to this success.

X-linked chronic granulomatous disease is a rare and severe immune disorder affecting only males and usually in childhood. The gene therapy* developed at Genethon by Dr. Anne Galy is the first to offer durable treatment for the disease. Genethon developed the delivery vector for the therapy and piloted the initial European trials launched in 2013. The results from Europe and the United States were published in the 28 January 2020 edition of Nature Medicine.

The gene therapy is designed to restore the activity of a faulty enzyme, NAPDH oxidase, by inserting a functional gene for that enzyme in the patient’s immune cells. To deliver the genes to those cells, the therapy uses a lentiviral vector that has already demonstrated its efficacy and safety in other immunodeficiencies.

The clinical vector lots were produced by Yposkesi, France’s first nonprofit pharmaceutical establishment created by AFM-Téléthon and Bpifrance.

Today, gene therapy research is bringing a first wave of successful treatments not only for previously incurable rare genetic diseases, including immunodeficiencies, blood diseases, vision disorders and recently a myopathy, but also for several frequent pathologies, like leukemia.

  • A REFRESHER ON GENE THERAPIES

    Gene therapies treat diseases by inserting functional genes in cells to correct for the missing or dysfunctional genes in the genome. The introduced gene is the active pharmaceutical ingredient of the therapy. The “gene drug” is delivered to the target tissue and ultimately the cell itself by a transport mechanism called a vector.

    Currently, the most effective vectors are viruses that have had their genomes altered so that they are no longer able to replicate or cause disease. A virus’ natural behavior is to invade the cell and insert its genetic material within. The cell then expresses the virus’ genes as if it were its own. That property is turned to good use with viral vectors in gene therapy.

  • REFERENCE

    Lentiviral gene therapy for X-linked chronic granulomatous disease. Nature Medicine, 2020.
    doi.org/10.1038/s41591-019-0735-5

Article posted on 28 January 2020

Share
Highlights

The lastest news


Hélène Virasith, Program manager à Genopole, a accompagné trois startups génopolitaines Nutropy, AuraLIP et Onima au salon Futur Food Tech de Chicago - Juin 2024

Genopole at the Futur FoodTech 2024 – Chicago

Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.

Discover
La délégation Genopole à BIO USA 2024

Genopole at BIO International 2024

The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.

Discover
Visite de la délégation

Genopole and the Netherlands: together to accelerate the development of alternative proteins

Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.

Discover
©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Discover
Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Discover
Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

Discover
l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Discover
Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023

An exploratory mission to Japan and South Korea for Genopole

Genopole sent a team to Japan and South Korea to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.

Discover
Ibisc - Genopole's Laboratory

IBISC – Structure prediction for RNA complexes

passes a milestone in structure prediction for RNA complexes, key players in cell biology.

Discover
IBISC: A first predictive tool for the emerging field of bifunctional RNA

IBISC: A first predictive tool for the emerging field of bifunctional RNA

The IBISC laboratory has developed IRSOM2, an unprecedented bioinformatics tool for the prediction of bifunctional RNA, a relatively recently discovered class of RNA showing both an ability to code for proteins and an ability to perform biological roles.

Discover
Integrating informatics, structural biology and in vivo exploration for the discovery of new medicines

SABNP & Synsight: discovery of new medicines

SABNP and Synsight have validated an integrated, drug discovery approach uniting informatics, structural biology and in vivo exploration.

Discover
Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

Discover
Lambe - Genopole's laboratory

Lambe: Detecting coagulation biomarkers with a natural nanopore

The Lambe laboratory showed proof of concept for a coagulation biomarker detection technology based on a natural nanopore.

Discover
Andrew Tolonen's team within the unit of Genomics Metabolics (Genoscope - CEA)

Genoscope: Biomanufacturing with bacteria

A team led by Andrew Tolonen has developed a method to optimize the genetic engineering of Clostridium genus bacteria for biotech applications

Discover
l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

Discover
A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Discover
Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Discover
Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Discover
Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Discover
Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Discover
View all >
With the support from
Région île de France